Research Supported
The DoxyPEP trial (Luetkemeyer et al., NEJM 2023) demonstrated that 200mg doxycycline taken within 72 hours of condomless sex reduced the combined incidence of chlamydia, syphilis, and gonorrhea by approximately two-thirds among MSM and transgender women — including roughly 88% lower chlamydia, 87% lower syphilis, and 55% lower gonorrhea per-pathogen.
Doxy-PEP fills a gap in sexual health. Condoms prevent everything but are not always used. PrEP protects against HIV but not bacterial STIs. Doxy-PEP is designed to prevent chlamydia, syphilis, and gonorrhea on an as-needed basis, taken after potential bacterial exposure.
For patients who want a research-backed option for post-exposure bacterial STI prevention, doxycycline offers a single 200mg dose taken within 72 hours (ideally within 24 hours).
Includes ongoing provider care & support
Platform access & educational content
Clinical Trial Evidence
Phase III trial results in MSM and transgender women. These are the figures that drive post-exposure prophylaxis protocols.
How Doxycycline Works
Doxycycline is a tetracycline-class antibiotic that halts bacterial protein synthesis before infection establishes. It targets three of the most common bacterial STIs via a single mechanism.
Doxycycline binds to the bacterial 30S ribosomal subunit, halting protein synthesis and preventing bacterial replication. This stops infection establishment before it becomes systemic.
One dose covers three major bacterial STIs: Chlamydia trachomatis, Treponema pallidum (syphilis), and Neisseria gonorrhoeae (gonorrhea). No separate medications needed.
Doxy-PEP is reactive prophylaxis, not daily prevention. Unlike PrEP (daily HIV prevention), you take a single 200mg dose after potential exposure, within 72 hours.
How to Use Doxy-PEP
Doxy-PEP is taken as a single dose after potential condomless sexual exposure. Timing is critical; earlier is better.
Condomless sex occurs, or a condom breaks. The window for Doxy-PEP begins now.
Take a single 200mg doxycycline tablet as soon as possible; ideally within 24 hours, no later than 72 hours.
Take with food and a full glass of water to minimize gastrointestinal upset and improve absorption.
Schedule STI testing at baseline, 2 weeks, and 3 months. Doxy-PEP does not replace regular screening.
Prevention Options
Each tool prevents different pathogens. Doxy-PEP fills the gap for bacterial STIs when condoms are not used.
Physical barrier
Post-exposure prophylaxis
Daily prevention
Critical Windows
Optimal Window
Maximum efficacy is achieved when doxycycline is taken within 24 hours of exposure. Do not delay; sooner is better.
Maximum Window
The absolute outer window is 72 hours. Efficacy declines significantly after 24 hours. After 72 hours, post-exposure prophylaxis is not recommended.
Follow-up Schedule
Schedule routine STI testing every 3 months regardless of Doxy-PEP use. Post-exposure prophylaxis does not replace regular screening.
Doxycycline is well-tolerated for single-dose post-exposure prophylaxis. Be aware of potential interactions and photosensitivity.
The most frequent effects are gastrointestinal upset (nausea, abdominal discomfort), especially on an empty stomach. Photosensitivity is possible; use broad-spectrum sunscreen. Most side effects resolve quickly after a single dose.
Do not take doxycycline within 2 hours of dairy products, antacids, or iron supplements, as these reduce absorption. Inform your provider of all current medications. Some interactions are possible with anticoagulants.
Reach out if you experience persistent nausea, severe photosensitivity reaction, signs of yeast infection, or have questions about dosing. Your provider is here to monitor your response.
Doxy-PEP is an off-label use of doxycycline. The drug itself is FDA-approved as an antibiotic; the post-exposure prophylaxis protocol is based on clinical trial evidence but represents off-label prescribing. Doxy-PEP is designed for intermittent post-exposure use only, not daily prophylaxis. Overuse contributes to antibiotic resistance. Do not use daily; take only after potential exposure.
Pricing
One flat rate. Physician supervision, compounded medication, and ongoing support included.
One-time purchase. Sufficient for multiple post-exposure doses.
Includes: physician consultation · ongoing provider support · free shipping
Off-Label Medication Notice: Doxycycline (Doxy-PEP) is prescribed for post-exposure prophylaxis of bacterial STIs. This represents off-label use of an FDA-approved antibiotic. Doxycycline itself is FDA-approved as an antibiotic for various infections; the Doxy-PEP post-exposure prophylaxis protocol is evidence-based but off-label. It is prescribed by a licensed provider for individual patient use. Doxy-PEP is not recommended for daily prophylactic use due to antibiotic resistance concerns.
Efficacy & Testing: Clinical trial data (Luetkemeyer et al., NEJM 2023) showed approximately two-thirds reduction in combined bacterial STI incidence, with per-pathogen relative risk reductions of approximately 88% for chlamydia, 87% for syphilis, and 55% for gonorrhea in MSM and transgender women. Efficacy varies by individual, population, and behavioral factors. Results are not guaranteed. Doxy-PEP is not a replacement for regular STI testing, consistent condom use, or other prevention strategies. Test at baseline, 2 weeks, and every 3 months regardless of Doxy-PEP use.
Not Medical Advice: The content on this page is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare provider before starting any new treatment. All Obsidian Genetics prescriptions are issued by licensed providers following a clinical review.
Bacterial Coverage Only: Doxy-PEP does not protect against viral STIs, including HIV, herpes (HSV), and HPV. It covers only bacterial pathogens: Chlamydia trachomatis, Treponema pallidum (syphilis), and Neisseria gonorrhoeae (gonorrhea). For HIV prevention, discuss PrEP or other strategies with your provider.
Citations & Evidence: DoxyPEP trial data: Luetkemeyer et al., New England Journal of Medicine (2023); Phase III randomized controlled trial demonstrating 65% reduction in chlamydia and syphilis, ~55% reduction in gonorrhea in MSM and transgender women. Doxycycline mechanism of action: tetracycline-class antibiotic; inhibits 30S ribosomal subunit protein synthesis.
Doxycycline is an FDA-approved drug in the tetracycline antibiotic class. Obsidian Genetics is a telehealth platform connecting patients with licensed providers. Prescription required. ©2024 Obsidian Genetics. All rights reserved.